New real-world data shows MiniMed 780G system sustains strong global performance, exceeding international targets for diabetes management

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures

Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States . The data was presented at the 17 th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy . These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

Time in Range is the percentage of time a person with diabetes spends between 70-180 mg/dL (3.9–10.0 mmol/L). Time in Tight Range is a new and emerging metric defined as the percentage of time a person with diabetes spends in the tighter glucose range of 70-140 mg/dL (3.9-7.8 mmol/L), which lowers the upper threshold to more closely mirror the blood sugar levels of someone without diabetes (also referred to as euglycemia). The MiniMed™ 780G system users (n=13,461) achieved a TITR of greater than 56% with the use of recommended optimal settings (100 mg/dL set target with an active insulin time of 2 hours).

New data sought to evaluate the MiniMed™ 780G system's ability to help users achieve Time in Tight Range (TITR) goals, a new and emerging supplementary metric being discussed amongst experts, which more closely mirrors the glucose levels of individuals without diabetes. Also referred to as normoglycemia or euglycemia, it is defined as the percentage of time a person spends in the glucose range of 70-140 mg/dL. TITR lowers the upper threshold of Time in Range from 180 mg/dL to 140 mg/dL. Results showed users (n=13,461) achieved a TITR of greater than 56% with the use of recommended optimal settings (100 mg/dL set target with an active insulin time of 2 hours). This data adds to a growing body of evidence that a TITR goal of 50% or greater is a reasonably achievable goal with the right therapeutic option.

"Since the landmark DCCT study, numerous retrospective studies have demonstrated the association between increased Time in Range and a reduction of diabetic complications. 1-12 There's no doubt elevated glucose is harmful and the average blood sugars of those living with type 1 diabetes are higher than we should accept as a clinical community," said Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. "The preponderance of data across randomized controlled trials and real-world studies show that the MiniMed™ 780G system is maximizing Time in Range far surpassing international targets and is taking it a step beyond by getting people closer to euglycemia. 13,14 In the absence of a cure, our goal is to relentlessly innovate therapies to help people maximize their health without adding burden, which our newest AID system has proven to do."

MiniMed    780G System Early Success in the U.S.
In an oral presentation, Dr. James Thrasher , MD, Founder, Arkansas Diabetes and Endocrinology Center, shared data on early real-world users with type 1 diabetes of the MiniMed™ 780G system in the U.S. (n=7,499). Results showed users achieved over 80% TIR when employing the recommended optimal settings, exceeding international glycemic targets (ADA guidelines recommend 70% time in range between 70-180 mg/dL), with closed loop exits occurring less than once per week on average. The enhancements introduced in this latest system have resulted in high satisfaction and improved quality of life benefits. 15,16 Indeed, the latest dQ&A U.S. Pump Patient Survey (n=1,997), found that among pump users, the MiniMed™ 780G system scored first in overall pump satisfaction. *,17 The survey also showed that among people with type 1 diabetes using CGM, the Guardian™ 4 sensor mirrored competitor sensors in overall satisfaction. *,18

"The results demonstrate that when the MiniMed™ 780G system is optimized with recommended optimal settings, it helps people with diabetes far exceed the ADA recommended goal of 70% Time in Range,*" said Dr. Thrasher. "The advent of AID systems has been nothing short of transformative in the practice of endocrinology and is really pushing all of us to introduce its protective benefits on overall health as early and often as possible. This data reinforces that the determinant of choice for AID systems should be first and foremost the power of the algorithm."

About Time in Tight Range
The development of continuous glucose monitoring enabled the development of Time in Range (TIR), a metric used today to determine whether an individual with type 1 diabetes is meeting blood sugar management goals. Since 2019, the goal of diabetes management has been to maintain the highest TIR for as long as possible while also minimizing hypoglycemia. The introduction of automated insulin delivery (AID) systems has transformed diabetes care by enabling a wider range of individuals to safely achieve blood-sugar goals with less burden and effort. AID systems are helping people achieve more ambitious goals with glucose management, prompting the emergence of a new supplementary metric that mirrors blood sugar levels of individuals without diabetes (normoglycemia or euglycemia). The MiniMed™ 780G system is demonstrating that a Time in Tight Range above 50 percent is achievable and serves as a powerful tool for those seeking more time in euglycemia.

About the Medtronic Diabetes ( www.medtronicdiabetes.com )
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

*Adults, T1 and parents of children with T1 diabetes

Sources

  1. Yapanis M, James S, Craig ME, et al. Complications of Diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab 2022;107(6):e2221–e2236
  2. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019;42(3):400–405
  3. Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 2018;41(11):2370–2376
  4. Raj R, Mishra R, Jha N, et al. Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: A systematic review. BMJ Open Diab Res Care 2022;10(1):e002573
  5. Lu J, Ma X, Shen Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther 2020;22(2):72–78
  6. Yoo JH, Choi MS, Ahn J, et al. Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther 2020;22(10):768–776
  7. Yang J, Yang X, Zhao D, et al. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy. J Diabetes Invest 2021;12(5):828–836
  8. Hirsch IB, Sherr JL, Hood KK. Connecting the dots: Validation of time in range metrics with microvascular outcomes. Diabetes Care 2019;42(3):345–348
  9. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open diabetes Res Care 2020;8(1):e000991
  10. El Malahi A, Van Elsen M, Charleer S, et al. Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab 2022;107(2):e570–e581
  11. Beck RW. The association of time in range and diabetic complications: The evidence is strong. Diabetes Technol Ther 2023;25(6):375–377
  12. Zhu DD, Wu X, Cheng XX, et al. Time in range as a useful marker for evaluating retinal functional changes in diabetic retinopathy patients. Int J Ophthalmol 2023;16(6):915–920
  13. CGM & Time in Range. American Diabetes Association. Available at: https://diabetes.org/tools-support/devices-technology/cgm-time-in-range . Accessed June 19, 2023 .
  14. American Diabetes Association (2019). Standards of medical care in diabetes—2019. Diabetes Care, 42(Suppl 1): S61-S70.
  15. MiniMed™ 780G system SSED
  16. Medtronic data on file: MiniMed™780G users survey conducted in April – May 202in UK, Sweden , Italy , Netherlands and Belgium . N 789
  17. dQ&A US Diabetes Patient Panel Report; Customer Overall Satisfaction, n=146; Q4 2023: P.52 ( November 2023 )
  18. dQ&A US Diabetes Patient Panel Report; Customer Overall Satisfaction, n=207; Q4 2023: P.85 ( November 2023 )

Contacts:


Ashley Patterson

Ryan Weispfenning

Public Relations

Investor Relations

+1-818-576-3025

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/new-real-world-data-shows-minimed-780g-system-sustains-strong-global-performance-exceeding-international-targets-for-diabetes-management-302084607.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

MDT
The Conversation (0)
Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. (TSX: PNE) ("Pine Cliff" or the "Company") announces its first quarter 2024 financial and operating results, an operational update and information regarding the annual meeting of shareholders.

First Quarter 2024 Results

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Canadian Natural Resources Limited Announces 2024 First Quarter Results

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. (TSX: PNE) (OTCQX: PIFYF) ("Pine Cliff" or the "Company") is pleased to announce the appointments of Mr. Daniel Keenan P. Eng to the position of Vice President Exploitation and Mr. Austin Nieuwdorp CA, CPA to the position of Vice President Finance and Controller both effective May 1, 2024.

Mr. Keenan became part of Pine Cliff in 2016. He holds a Bachelor of Mechanical Engineering Degree from the University of Victoria obtained in 2001. Throughout his 20-year career, he has taken on increasingly challenging roles in exploitation, production operations and facilities engineering, culminating in his most recent position as Pine Cliff's Manager of Exploitation. Notably, Mr. Keenan has played a pivotal role in identifying and expanding Pine Cliff's asset portfolio and drilling opportunities, showcasing his leadership and strategic vision.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. (TSX: ACO.X) (TSX: ACO.Y)

2024 ATCO AGM (CNW Group/ATCO Ltd.)

ATCO Ltd. (ATCO) will hold its 57th Annual General Meeting of share owners at 10 a.m. MDT on Wednesday , May 15, 2024. In addition to the formal business of the meeting, attendees will hear management's view of ATCO's full year 2023 and first quarter 2024 operational and financial performance.

At this year's meeting, members of the ATCO executive leadership team will also outline growth strategies and goals for ATCO Structures, ATCO EnPower and ATCO Energy Systems.

Attendees will hear from:

  • Nancy Southern , Chair & Chief Executive Officer
  • Katie Patrick , Executive Vice President, Chief Financial & Investment Officer
  • Adam Beattie , President, ATCO Structures
  • Bob Myles , Chief Operating Officer, ATCO EnPower
  • Wayne Stensby , Chief Operating Officer, ATCO Energy Systems

Share owners and interested parties can view the meeting virtually using Microsoft Teams via this link using a web browser (Chrome, Safari, Edge or Firefox) on a smartphone, tablet or computer. Using Internet Explorer is not recommended as it is no longer supported and may not function properly.

Attendees who are share owners or proxyholders wishing to vote their shares should review the information contained in the ATCO Management Proxy Circular dated March 11, 2024 , beginning on page one.

As a global enterprise ATCO Ltd. and its subsidiary and affiliate companies have approximately 20,000 employees and assets of $25 billion . ATCO is committed to future prosperity by working to meet the world's essential energy, housing, security and transportation challenges. ATCO Structures designs, builds and delivers products to service the essential need for housing and shelter around the globe. ATCO Frontec provides operational support services to government, defence and commercial clients. ATCO Energy Systems delivers essential energy for an evolving world through its electricity and natural gas transmission and distribution, and international operations. ATCO EnPower creates sustainable energy solutions in the areas of renewables, energy storage, industrial water and clean fuels. ATCO Australia develops, builds, owns and operates energy and infrastructure assets. ATCOenergy and Rümi provide retail electricity and natural gas services, home maintenance services and professional home advice that bring exceptional comfort, peace of mind and freedom to homeowners and customers. ATCO also has investments in ports and transportation logistics, the processing and marketing of fly ash, retail food services and commercial real estate. More information can be found at www.ATCO.com .

Investor & Analyst Inquiries:  
Colin Jackson
Senior Vice President, Finance, Treasury & Sustainability
Colin.Jackson@atco.com
(403) 808 2636

Media Inquiries:
Kurt Kadatz
Director, Corporate Communications
Kurt.Kadatz@atco.com
(587) 228 4571

SOURCE ATCO Ltd.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/29/c6613.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

-

PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Healing People and Planet: New Impact Report Outlines How Medtronic Is Shaping the Future of Health

Medtronic

Medtronic releases 2024 Impact Report highlighting success in healthcare equity with new data from the Healthy Neighbor program, in addition to community engagement and environmental sustainability progress

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Artificial Intelligence Reshaping Healthcare Industry with Unimaginable Potential

FN Media Group News Commentary - The Healthcare Artificial Intelligence (AI) market exhibits a high degree of innovation, characterized by ongoing advancements in technology. Rapid developments in ML, deep learning, NLP, and computer vision are driving the evolution of AI-powered healthcare solutions. One primary factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy, and better patient outcomes. According to a March 2024 Microsoft-IDC study, 79% of healthcare organizations are presently utilizing AI technology. In addition, the return on investment (ROI) is realized within 14 months, generating USD 3.20 for every USD 1 invested in artificial intelligence (AI). AI technologies hold transformative potential in various areas including medical imaging analysis, predictive analytics, personalized treatment planning, and drug discovery, potentially transforming conventional healthcare practices. A report from Grand View Research said the global AI in healthcare market size, which was estimated at USD 19.27 billion in 2023, is expected to grow at a CAGR of 38.5% from 2024 to 2030. The report said: "Mergers & acquisitions (M&As) play a significant role in shaping the healthcare AI market landscape. Companies [that] engage in M&A activities to expand their AI software and services increase their market reach or acquire specialized technology and expertise. End-users are becoming increasingly aware of the potential benefits of AI in improving patient care, operational efficiency, and healthcare outcomes. Education initiatives and industry events helped raise awareness about the capabilities and applications of AI in healthcare." A.I. companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Teladoc Health, Inc. (NYSE: TDOC), Tempus AI, Inc. (NASDAQ: TEM), Medtronic plc (NYSE: MDT), Clover Health Investments, Corp. (NASDAQ: CLOV).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic receives FDA clearance for new InPen app, paving the way for its Smart MDI system launch with Simplera CGM

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM). The company's Smart MDI system combines its InPen™ smart insulin pen with its newest Simplera™ CGM — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic reports second quarter fiscal 2025 financial results

Delivering on commitments, executing ahead of expectations, and raising guidance

Innovation driving sustained growth across many franchises:  TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Announces Health Canada Approval for JORNAY PM to Treat Attention-Deficit Hyperactivity Disorder

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM ™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children.

JORNAY PM ™ is the first and only evening-dosed methylphenidate product commercially available in Canada to treat ADHD in patients from 6 to 12 years of age. JORNAY PM ™ consists of microbeads with a delayed-release layer and an extended-release layer. The first layer delays the release of the active ingredient until morning while the extended-release layer controls the release of the active ingredient starting in the morning and continuing throughout the day. This unique formulation provides a pharmacokinetic profile that allows ADHD symptom control from the time patients wake up until the evening.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation ("Thermo Fisher"), a world leader in supplying life sciences solutions and services.

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed's Next Generation colorectal cancer screening product. The collaboration will harness Thermo Fisher's powerful technologies, instrumentation and information translation systems to enable Mainz Biomed to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are redefining standards in early cancer detection. Mainz Biomed's flagship non-invasive test not only targets the early detection of colorectal cancer but also focuses on precancerous lesions, particularly advanced adenomas, demonstrating significant clinical success in both US and European trials.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×